Ensitrelvir
Chemical formula: C₂₂H₁₇ClF₃N₉O₂ PubChem compound: 162533924
Active ingredient description
Ensitrelvir selectively inhibits SARS-CoV-2 3C-like (3CL) protease, an essential enzyme for the processing of the polyprotein encoded by the SARS-CoV-2 gene, which thereby inhibits SARS-CoV-2 replication. The 50% inhibitory concentration (IC50) of ensitrelvir for SARS-CoV-2 3CL protease activity was 0.0132 μmol/L.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| J05AE16 | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors | |
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| ZOKOVEA Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Medicines
Ensitrelvir is an active ingredient of these brands:
Japan (JP)
Lithuania (LT)United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.